EC Number   |
Application |
Reference |
|---|
   3.4.24.75 | medicine |
lysostaphin is a therapeutic agent for methicillin-resistant Staphylococcus aureus pneumonia |
733464 |
| 3.4.24.75 | medicine |
lysostaphin is an antistaphylococcal agent. The enzyme is efficacious in the treatment of bovine mastitis caused by staphylococci |
720624 |
| 3.4.24.75 | medicine |
lysostaphin is an effective treatment as well as prophylaxis for Staphylococcus aureus biofilms on indwelling catheters |
708895 |
| 3.4.24.75 | medicine |
lysostaphin is useful in treatment of neonatal Staphylococcus aureus infection, overview |
683082 |
| 3.4.24.75 | medicine |
lysostaphin, in combinantion with the antibiotic ranalexin, is effective against wound or systemic infections caused by meticillin-resistant Staphylococcus aureus. The combination is significantly more effective than treatment with ranalexin or lysostaphin alone. Ranalexin and lysostaphin can be incorporated in wound dressings for the prevention and treatment of topical Staphylococcus aureus infections |
708742 |
| 3.4.24.75 | medicine |
lysostaphin-functionalized cellulose fibers show activity against Staphylococcus aureus in an in vitro skin model (HaCaT keratinocyte) with low toxicity toward keratinocytes, suggesting good biocompatibility for these materials as antimicrobial matrices in wound healing applications |
719034 |
| 3.4.24.75 | medicine |
potential therapeutic agent against antibiotic-resistant Staphylococcus aureus infections |
695804 |
| 3.4.24.75 | medicine |
staphylococcal disease pathogenesis |
668814 |
| 3.4.24.75 | medicine |
the enzyme can be used in life-threatening infections, such as endocarditis to increase the early in vivo activity of the antibiotics, and to prevent the emergence of linezolid resistant mutants |
753949 |
| 3.4.24.75 | medicine |
the enzyme is a potential antimicrobial agent for Staphylococcus aureus infections |
-, 755476 |
